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This article is based on presentations
at the Tulane University Diabetes Update
on 8 December 2007 in New Orleans,
Louisiana; at the Mount Sinai Medical
Center Diabetes Grand Rounds in New
York, New York, on 6 December 2007;
and at the American Diabetes Associa-
tion’s 55th Annual Advanced Postgradu-
ateCourseheld1–3February2008inSan
Francisco, California. These lectures, ad-
dressing differing views of various speakers
on various aspects of diabetes prevention,
obesity, and new treatments for type 2 dia-
betes, are available online at http://
professional.diabetes.org.
Preventing diabetes
RichardBergenstal(Minneapolis,MN)re-
viewed approaches to treatment of pre-
diabetes at the American Diabetes
Association Postgraduate Course. The
number of individuals with diabetes
worldwide is projected to increase to 333
million by 2025, and the annual cost of
diabetes in the U.S. today has reached
$174 billion (1). The burden of compli-
cations among diabetic individuals aged
65 years in the U.S. includes doubling
of the rates of myocardial infarction and
congestive heart failure (2). Bergenstal re-
viewed current guidelines for using ele-
vated fasting and 2-h glucose, as well as
thegrowinguseofA1C,intheassessment
of the pre-diabetic state. The presence of
both impaired fasting glucose (IFG)
(100 mg/dl) and impaired glucose tol-
erance(IGT)(bloodglucose2hafter75-g
oral glucose 140 mg/dl) doubles the
risk of progression to diabetes. Insulin se-
cretory defects are seen in IFG and, to a
greaterextent,inIGT,andIGTappearsto
lead to greater cardiovascular disease
(CVD) risk than does IFG. During the
phase of abnormal glucose tolerance be-
fore development of diabetes, insulin re-
sistance occurs in addition to insulin
deﬁciency, leading to the condition vari-
ously referred to as metabolic syndrome,
cardiometabolic syndrome, or insulin
resistance syndrome, with controversy
as to whether the syndrome is associated
with risk beyond that of its component
risk factors. Macrovascular disease often
precedes the development of diabetes,
while microvascular complications have
been said to begin at the time of onset
of diabetes (3), although there is now
well-reported evidence of retinal abnor-
malities, microalbuminuria, and periph-
eral neuropathy preceding onset of
diabetes. Interestingly, in addition to dia-
betesincreasingCVDrisk,thepresenceof
CVDisassociatedwithincreaseddiabetes
risk, an important consideration in
screening for pre-diabetes.
It is possible to reduce the develop-
ment of diabetes by intervening before its
onset. In a meta-analysis, lifestyle inter-
ventions reduced diabetes by approxi-
mately one-half and pharmacologic
interventions by approximately one-third
(4). Major lifestyle studies included the
Finnish Diabetes Prevention Study (DPS)
(5) and the U.S. Diabetes Prevention Pro-
gram (DPP) (6), both with reductions in
development of diabetes by 58%. In DPS,
participants with greater numbers of in-
ﬂuenced lifestyle variables showed
greater reduction in development of dia-
betes. Follow-up of the DPS showed sus-
tained reduction in diabetes, with rates
remaining 39% lower 4 years after com-
pletion of the study, in association with
increase in physical activity (7). In the
DPP, treating 6.9 individuals with life-
style intervention would prevent one case
of diabetes over 3 years. A number of
other studies have addressed approaches
to lifestyle intervention. A study of treat-
mentofindividualswithexistingdiabetes
rather than pre-diabetes, the Look
AHEAD (Action for Health in Diabetes)
study, illustrates the feasibility and effec-
tiveness of lifestyle modiﬁcation, with a
1-year outcome of 8.6% weight loss,
20.9% improvement in ﬁtness, and 0.7%
A1C lowering from a baseline of 7.3%, as
well as improvements in blood pressure
and lipids (8). The goal of the study is to
maintain these behaviors for a decade to
determine whether improvement in out-
come can be demonstrated. Prevention of
complications rather than just prevention
of worsening glycemia should be the goal
fordiabetespreventionaswell.Animpor-
tantquestionwillbethecost-effectiveness
of lifestyle modiﬁcation in preventing di-
abetes.Estimatesofthecostofthelifestyle
intervention of the DPP, the Archimedes
model (9,10), suggest that the approxi-
mate cost for prevention of diabetes is
$30,000–60,000 per individual. How-
ever, recent studies have explored less
expensive approaches to lifestyle inter-
vention (11); should this prove feasible,
costestimatesfordiabetespreventionwill
be greatly reduced.
Pharmacologic approaches are
equally promising for diabetes preven-
tion.Metforminwasnotaseffectiveasthe
lifestyle intervention in the DPP, requir-
ing treatment of 13.9 individuals for 3
years to prevent one case of diabetes, but
it was particularly effective in younger in-
dividuals and in those who were over-
weight. These ﬁndings were conﬁrmed in
a recent meta-analysis (12). In the Diabe-
tes REduction Assessment with ramipril
and rosiglitazone Medication (DREAM)
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(although it was associated with a small
but signiﬁcant reduction in blood glu-
cose) (13), while rosiglitazone-treated in-
dividuals experienced “remarkable
beneﬁt in prevention of diabetes,” al-
though their risk of congestive heart fail-
ure increased (14). Acarbose has been
shown to reduce both diabetes and CVD
(15). Pharmacologic approaches to
weight loss also should have beneﬁt in
preventing diabetes. Treatment with the
cannabinoid receptor antagonist rimon-
abant is an effective approach to weight
loss(16),althoughadversepsychiatricef-
fects led to lack of approval by the FDA.
Orlistat, which is now available as an
over-the-counter product, promotes
weightlossandhasbeenshowntoreduce
progression to diabetes (17). Incretin-
related treatment also appears attractive
for early diabetes and, perhaps, for pre-
diabetes, given the association of ex-
enatide treatment with both weight loss
and improvement in A1C, with studies of
itsuseinmonotherapyandforweightloss
in progress. Lifestyle modiﬁcation should
be the primary approach for individuals
with either IFG or IGT, but for those with
both abnormalities and for those aged
60 years with BMI 35 kg/m
2, positive
family history, elevated triglyceride, low
HDL cholesterol, hypertension, or A1C
6%, Bergenstal recommended adding
metformin, suggesting that other phar-
macologic approaches may be appropri-
ate(18).Anotherappealingapproachisto
“just put the band in there,” he com-
mented, reviewing a recent study in
which73%ofdiabeticindividualstreated
with adjustable gastric bands using lapa-
roscopic surgery had remission of diabe-
tes in association with 20.7% weight loss
(19).
To identify those at high risk of dia-
betes, information regarding obesity, lack
of exercise, childhood birth weight, and
family history are useful, allowing the
physician to “impress upon [these] indi-
viduals the seriousness of the risk.” A
screening tool based on the Archimedes
model is available (20), giving a classiﬁ-
cation tree for detecting pre-diabetes
based on age, waist, family history, etc;
thiscalculatingenginehasbeenplacedon
the ADA Web site at www.diabetes.org/
diabetesphd. The ADA Standards of Care
Position Statement in January 2008 gave
new nutrition recommendations, recog-
nizing that both low-carbohydrate and
low-fat diets are reasonable for different
patients.Thereareanumberofothernew
ﬁndings that may give insight into life-
style changes reasonable for the preven-
tionofdiabetes.Whole-graincerealswere
shown to be associated with reduced dia-
betes risk in some studies (21), but this
ﬁnding was not conﬁrmed in a meta-
analysis (22). Although caffeine increases
glucose in diabetic individuals during
continuous glucose monitoring (23), in
epidemiologic studies, coffee use has
been associated with reduction in diabe-
tes risk (24). Meat, fried foods, and diet
soda are associated with increased risk of
metabolic syndrome (25), with there be-
ingnodifferencebetweendietandregular
soda in cardiometabolic risk (26). An ef-
fective strategy for increasing physical ac-
tivity is the use of pedometers (27), with
Bergenstal explaining, “you’ve got to set a
goal,” while recognizing that many pa-
tients will not achieve it. Combinations of
resistance and aerobic exercise may also
be useful in lifestyle interventions (28). A
ﬁnal interesting aspect of lifestyle is that
either too much or too little sleep may
increase diabetes risk (29).
Is there an optimal diet for
treatment of diabetes and obesity?
At the New Orleans meeting, Judith
Wylie-Rossett (Bronx, NY) reviewed a
number of diabetic diets, concluding that
the optimal diet is “whatever diet you can
stick to.” She suggested the importance of
breaking the behavioral chain of overeat-
ing and the need to eliminate the “easiest
caloriesﬁrst,”choosingadietaryplanthat
is safe and in keeping with the individual
preferences of each patient, and she
stressed the importance of being ready to
switch approaches if a patient does not
respondtoaparticularapproach.Noneof
the studied diets met the American Heart
Association criterion of containing 7%
of calories as saturated fats. The South
Beach Diet is divided into three phases,
with the ﬁrst 2 weeks made up of lean
meats, low glycemic index vegetables,
low-fat cheese, nuts, and eggs, with sub-
sequent gradual introduction of addi-
tional foods. In the Atkins diet, four
phases are recommended: an induction
phase with 20 g carbohydrates daily,
subsequently adding 5 g carbohydrates
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes
treatment will be highlighted in this section.
The FDA has made a very reasonable proposal to remove the confusing letter
categories for risk associated with prescription medicines during pregnancy and
lactation, replacing them with a three-part discussion: ﬁrst, a “Fetal Risk Sum-
mary” of what is known about effects of the agent on the fetus and whether this
is based on animal or on human studies; second, a discussion of clinical consid-
erationsincludingsuggestionsregardingtheagents’usepriortoawomanknow-
ingsheispregnant;andthird,adetailedreviewoftheavailabledatafortheeffects
of the medication during pregnancy and lactation.
The FDA plans to link Medicare Prescription Drug Beneﬁt data with Medicare
inpatient and outpatient claims data in order to create a database allowing mon-
itoring of postmarketing adverse drug events. Eventually, this program, which
will be called the Sentinel System, will be expanded to include additional large
electronicclaimandmedicalrecorddatasources,withtheaimofnolongerdepend-
ingonvoluntaryreportingofsafetyconcerns—asystemthathasbeendemonstrably
inadequate in providing informaltion about adverse drug reactions.
Revisionshavebeenmadetotheproductlabelforoseltamivir,theantiviralagent
used in treatment of inﬂuenza, emphasizing the occasional association of the
drug with delirium and abnormal behavior. However, it is possible that some of
these symptoms may be caused by inﬂuenza itself.
A new approach to coronary artery imaging during catheterization now has FDA
approval: a device, the InfraReDx LipiScan, that uses infrared imaging to detect
lipid core–containing plaques. The FDA has become aware that it is possible for
patients to use LifeScan OneTouch Ultra test strips with Abbott Precision Xtra
meters; the glucose readings so obtained will be erroneous, and it is important
that patients be cautioned to use the correct strip with its correct meter.
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phase when the patient is within 10 lbs of
goal weight, allowing 30–60 g carbohy-
drates daily, and a maintenance phase
whenatgoalallowing40–100gcarbohy-
drates daily. Patients following such diets
commonly have difﬁculty avoiding ice
cream and fried foods, with other surveys
suggesting problems with low-carbohy-
drate diets with regard to avoiding sugars
and starches, drinking sufﬁcient water,
eating vegetables, exercising, increasing
protein, avoiding soft drinks, eating fruit,
and decreasing fat. Wylie-Rossett con-
trasted low carbohydrate diets with Med-
iterranean diets such as the Willett diet,
which recommends ﬁsh, ﬁsh oils, wal-
nuts, ﬂax seeds, and ﬂaxseed oil for n-3
fatty acids and legumes and olive oil for
n-6fattyacids.Low–glycemicindexdiets
(30) are examples of diets recommending
foods of low-energy density but that offer
another approach. Vegetables are low in
energy density, with the High Protein
Weight Watchers diet and the Atkins diet
containing few vegetables, while the Or-
nish diet, the South Beach diet, the “Glu-
cose Revolution” diet, and the Zone diet
contain more (31).
High-protein diets may decrease ap-
petite, with a 12-month comparison of
Atkins-type diets with diets higher in car-
bohydratesshowingthatalthoughthelat-
ter contain less saturated fat, the former
were associated with greater falls in tri-
glyceride and blood pressure in the con-
text of greater weight loss (32). Reviews
comparing various diets suggest that low-
carbohydrate diets do lead to greater
initial weight loss (33), with greater im-
provement in large VLDL and in inﬂam-
mation (34,35) but with greater increase
in chylomicron levels (36). Wylie-
Rossett’s studies of diabetic patients also
suggest greater initial weight loss with
low-carbohydrate diets, but she, too,
found that this was not sustained. Other
studies of diabetic patients suggest mod-
est but signiﬁcant reduction in A1C with
low–glycemic index diet approaches
(37). She noted that ketosis may be asso-
ciated with fatigue in individuals follow-
ing low-carbohydrate diets (38). The
explanation for the catch-up in weight af-
ter 3 months in patients following a low-
carbohydrate diet appears to be the
greater difﬁculty in adherence to such ap-
proaches,leadingtoherrecommendation
that a diet be considered “a new way of
eating. . . a little bit like religion.” The
new ADA guidelines allow greater liberal-
izationofdietaryapproaches,recognizing
that a variety of diets may be useful in
successful dieting. Two new concepts be-
ing applied in nutrition are of “daily ref-
erence intakes,” related to the older
concept of “recommended dietary allow-
ances” and the concept of “net carbohy-
drates,” excluding ﬁber and sugar
alcohols.
Pathogenesis of obesity
At Mount Sinai, Jeffery Flier (Boston, NY)
discussed the pathogenesis of obesity, re-
viewing potential interactions between
genes and the environment. There are
rare, sporadic monogenic disorders asso-
ciated with obesity, but the typical inher-
itanceispolygenic.Environmentalfactors
are dietary intake and physical activity.
The decreasing cost of food and its in-
creasing availability, as well as, perhaps,
changes in the macronutrient composi-
tionofthedietwithincreasingamountsof
rapidly absorbed carbohydrates, have led
to an obesogenic diet. Interindividual
variations in metabolic rate and in the
thermic effect of food are important de-
terminants of caloric expenditure, and an
increasingly recognized factor, nonexer-
cise activity thermogenesis (39), which
includes activities like “ﬁdgeting,” may
have genetic determinants as well.
Whether population weight gain is
mainly caused by increased energy intake
or decreased energy expenditure has not
been resolved. Additional environmental
factors, which may have genetic compo-
nents as well, are the effects of prenatal
and early childhood nutrition; effects of
sleep deprivation, which may change di-
urnal patterns of leptin and other hor-
mones; effects of viral infection; effects of
gut ﬂora, which may have impact on gut-
brain signaling; and effects of stress and
inﬂammation.
A basic concept involved in these
studies is that evolution favors energy
storage, with the current environment of
plentiful food leading to increasing prev-
alence of obesity. Brain mechanisms in-
clude changes in behavior (in appetite,
food intake, and physical activity);
changesinautonomicfunction,leadingto
effects on thermogenesis and on metabo-
lism; and changes in neuroendocrine
function, with reproductive, growth, and
thyroid systems all having impact on de-
velopment of obesity. Hypothalamic sati-
ety and feeding centers receive signals
from peripheral sites—both 1) starvation
signals, e.g., leptin, glucose, and perhaps
fatty and amino acids, which in low levels
stimulate food intake, and 2) satiety sig-
nals, including cholecystokinin, peptide-
YY, ghrelin, glucagon-like peptide-1, and
amylin,aswellasvagallymediatedneural
signals. In addition, hedonic signaling via
olfactory, taste, visual, and tactile senses
are also important in promoting food in-
take. Flier noted the interesting parallels
between circuits involved in appetite and
hedonic pathways involved in addiction,
with neurons involved in metabolic path-
ways as well as those related to hedonic
centers expressing leptin receptors (40),
suggesting that both are important in un-
derstanding obesity.
Adipocyte signals include free fatty
acids, estrogen, and adipsin. Flier re-
viewed his studies of adipsin (41), a cir-
culating protease mainly produced in fat,
with levels reduced in obesity in rodents
but not in humans. It is a complement
protein, exemplifying the interaction of
inﬂammation with obesity. Flier has also
studied the roles in obesity of angio-
tensinogen (42) and of 11-hydroxy-
steroid dehydrogenase (HSB1), which
activates intracellular adipocyte conver-
sion of cortisone to cortisol. Leptin is a
fat-derived cytokine originally thought to
act as an endogenous anti-obesity factor
(43). It has been increasingly recognized
that there is leptin resistance in obesity
(44,45), leading to the realization that
falls in leptin level, acting as signals of
decreased nutrient availability, appear to
be more important than increases (46).
Most obese individuals are, in fact, resis-
tant to the action of leptin, possibly be-
causeofcirculatingantagonisticfactorsor
a decrease in transport across the blood-
brain barrier; typically, circulating leptin
levels are increased in obesity. Ap-
proaches to pharmacologic use of leptin
thus appear to require combination ther-
apy. Sites of leptin action in the brain are
the arcuate nucleus, where leptin stimu-
lates pro-opiomelanocortin (POMC)/
cocaine- and amphetamine-regulated
transcript protein and inhibits agouti-
related protein (AgRP)/neuropeptide Y
neurons, the former producing -mela-
nocyte–stimulatinghormonesandthelat-
ter AgRP, which respectively stimulate and
inhibit the effects on the melanocortin-4
receptor of the paraventricular and ventro-
medialportionsofthehypothalamus.Loss-
of-function mutations of this receptor are
the main monogenic causes of human obe-
sity. POMC and AgRP also have effects on
melanin-concentrating hormone (MCH)
and orexin and on other neurotransmitters
in the lateral hypothalamus.
Flier showed that, after a high-fat
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signal transducer and activator of tran-
scription (STAT)3 activation (47). The
suppressor of cytokine signaling (SOCS)
family of cytokine-inducible proteins is
important in obesity, with leptin increas-
ing hypothalamic SOCS3 and overex-
pression of SOCS3 reducing the leptin
effect, while heterozygous deﬁciency of
SOCS3 increases leptin responsiveness
(48). Flier suggested the concept that
SOCS3 is rate limiting for leptin action
and noted that an animal model speciﬁ-
cally not expressing neuronal SOCS3
showsincreasedleptinresponse.Deletion
of SOCS3 in POMC neurons results in
increased leptin response and also im-
proved glucose homeostasis, suggesting a
divergence between effects of leptin on
obesity and glucose homeostasis. Flier
notedthatSOCS3isanantagonistofboth
leptin and insulin signals and that it is
regulatedbyleptin,insulin,cytokines,re-
sistin, and fatty acids. The effects of insu-
lin parallel those of leptin, although
insulin deﬁciency is associated with ca-
chexia rather than weight gain. Other sig-
nalsinvolvedinweightregulationinclude
ghrelin,peptideYY(PYY),serotonin,can-
nabinoids, glucose, free fatty acids, and
AMP kinase. Another important obesity-
related factor is MCH, overexpressed in
the lateral hypothalamus of leptin-
deﬁcient ob/ob mice. When administered
centrally, MCH causes obesity, while
mice not expressing this peptide are lean
(49). MCH type-1 receptor antagonists
may offer a promising pharmacologic ap-
proach to obesity treatment.
An additional concept is whether
brain circuitry itself can be modiﬁed. Cil-
iary neurotrophic factor (CNTF) stimu-
lates cell survival and differentiation and
has anorexic effects and beneﬁts in mod-
els of obesity. It activates STAT3, leading
to the concept that it may reduce the lep-
tin resistance of obesity. Weight loss may
persist even after administration of CNTF
hasbeenstopped,suggestingthepossibil-
ity that it may stimulate neural stem cells,
leading to formation of new neurons, in-
cluding some expressing POMC and neu-
ropeptideY(50).Clinicaltrialsfailedwith
this agent because of the development of
CNTF antibodies, but new approaches
may be possible. Flier reviewed studies in
whichfetalstemcellsdevelopedintoneu-
rons, some expressing POMC and leptin-
activated STAT3, which, when trans-
planted into db/db mice lacking the leptin
receptor, led to weight loss and improved
glycemia, suggesting that it may be possi-
ble to “rewire the obese brain.”
Novel targets for diabetes treatment
At the New Orleans meeting, Vivian Fon-
seca (New Orleans, LA) pointed out that
glycemic control should be considered a
surrogate end point, akin to cholesterol
and blood pressure levels, presumably
actingtomediateclinicaloutcomesrather
than simply being a marker associated
with complications. Inﬂammation re-
ducesinsulinsensitivity,causesincreased
triglyceride and low HDL, and is associ-
ated with atherosclerosis, with the high-
sensitivity C-reactive protein (CRP) and
leukocyte counts demonstrated to be
markers of vascular outcome. Fonseca
suggested, however, that “the problem is
that for people with diabetes it’s a totally
useless test.” Elevated levels of CRP are
associated with a number of insulin resis-
tance syndrome features and, particu-
larly, with obesity among women, a
clinical ﬁnding that led to the realization
of the importance of the adipocyte as a
source of proinﬂammatory factors and of
the increase in adipose tissue macro-
phagesinobesity.Nuclearfactor-B(NF-
B) plays a key role in inﬂammation.
NF-B is bound to the inhibitor of B
(iB).ThedissociationofNF-BfromiB
leads to NF-B entering the nucleus, in-
creasing transcription of inﬂammatory
mediators and cytokines such as interleu-
kin-6,interleukin-1,tumornecrosisfac-
tor-, resistin, -interferon, chemokines,
and receptors. A variety of clinical mea-
sures reduce inﬂammation, including
low-fat diet, weight loss, statins, insulin
sensitizers,andaspirin.Theeffectofaspi-
rin on insulin sensitivity suggests its po-
tential for the treatment of diabetes, with
studies performed more than four de-
cades ago showing that in high doses it
reduces glycemia (51). Aspirin reduces
levels of NF-B (52,53), and it may be
relevant that there is evidence of islet in-
ﬂammation in diabetes. These ﬁndings
led to study of salsalate treatment for dia-
betes, with evidence of reduction in fast-
ing glucose, cholesterol, triglyceride, free
fatty acids, and CRP and increase in adi-
ponectinlevelsinnondiabeticindividuals
(54).A dose-responsestudy,theTarget-
ing INﬂammation using SALsalate for
type 2 Diabetes (TINSAL-T2D; www.
tinsal-t2d.org) study, is in progress in
individuals with type 2 diabetes.
Fonseca reviewed a number of other
potential new diabetes treatments. Bile
acid sequestrants appear to lower glucose
in diabetic patients, with data from more
than a decade ago suggesting glycemic
beneﬁt from cholestyramine (55) and
colesevelam now shown to lower glucose
in combination with insulin, metformin,
and sulfonylureas (56). Weight control is
ofgreatimportanceinthemanagementof
diabetes, and ghrelin receptor antagonist
administration has been shown to reduce
food intake in animal models, suggesting
a promising area for study. The cannabi-
noid receptor antagonist rimonabant has
deﬁnite weight loss beneﬁt, which is of
particular interest in view of the higher
endocannabinoid levels in obese individ-
uals, but has been found to be associated
with anxiety and depression, leading to
concern as to whether this will be a safe
approach. Given the similarity between
hypercortisolemia and type 2 diabetes/
metabolic syndrome, with both condi-
tions characterized by obesity, hyper-
tension, insulin resistance, and dyslipide-
mia, the provocative question has been
raised,“DoescentralobesityreﬂectCush-
ing’s disease of the omentum?” HSD1 in-
creases conversion of cortisone to cortisol
within the adipocyte and may act in other
insulin-sensitivetissues,withanumberof
groups looking into the development of
adipose tissue HSD1 inhibitors. Finally,
the sodium/glucose cotransporter SGLT2
is responsible for 90% of renal tubular
glucose reabsorption in proximal tubule,
and its inhibition, by decreasing glucose
absorption,resultsinglycosuria,withpo-
tentialglucose-loweringbeneﬁt,although
thisapproachmayincreasethelikelihood
of bladder and genital infection.
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